Tofacitinib

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Tofacitinib and local guidelines before prescribing.

JAK inhibitor

Mechanism

JAK inhibitor.

Uses

Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Infections including herpes zoster, raised lipids, cytopenias, VTE, MACE, malignancy.

Interactions

CYP3A4 inhibitors and inducers; other immunosuppressants.

Contraindications and cautions

Active infection, severe hepatic impairment, VTE

Monitoring

FBC, LFT, lipids

Pregnancy and breastfeeding

Contraindicated

Renal and hepatic impairment

Reduce dose in severe renal impairment

Overdose and reversal

Supportive

Special advice

MHRA caution in those over 65, smokers and VTE or cardiovascular risk; check lipids.

More from the textbook: uses, cautions and other points
Where it is discussed in the book